J Gastroenterology: Vonoprazan-based triple therapy is effective in eradicating Helicobacterrobacteria.

Helicobacter pyridosis infections are known to cause upper gastrointestinal diseases such as chronic gastritis, peptic ulcers and stomach cancer.
more than 90% of patients with gastric cancer have Helicobacter pyridobacteria infection, the eradication of Helicobacter pyridosis can help reduce the risk of stomach cancer.
, the decline in Helicobacterrobacteria eradication rates has become a major problem in recent years.
(CAM) resistance is one of the main factors leading to treatment failure.
Since the eradication rate depends on the local prevalence of drug-resistant bacteria, a variety of treatments have been tried, including sequentium, combination therapy, combination therapy and high-dose double therapy, and in Japan, the eradication rate of basic therapies using various proton pump inhibitors (PPI) is reported to be between 71.9% and 73.9%.
Japan recently reported the results of several studies on the effectiveness of Vonoprazan (VPZ) therapy.
VPZ, a new potassium competitive acid blocker, was approved in Japan in 2015 to eradicate Helicobacter pyridosis.
VPZ differs from conventional PPI in that it reduces stomach acid secretion by inhibiting the activity of H . . . / K . . - ATPase in stomach wall cells.
VPZ does not require acid activity, is more stable under neutral pH, and is less sensitive to environmental pH, and in a randomized double-blind Phase III study, the eradication rate of VPZ-based first-line triple therapy (using amosiline (AMPC) and CAM) was 92.6%, and even in CAM resistance patients, the eradication rate was 82.0%, significantly higher than the results of traditional PPI treatment.
refore, this study aims to assess the effectiveness and safety of VPZ-based triple therapy as a first-line solution to eradicate Helicobacter pyridoxine, as well as its relationship to clariamcin (CAM) sensitivity.
researchers looked forward to this trial in patients with Helicobacter pyridobacteria infection who underescopic examination of the gastroesoescopy and were tested for CAM sensitivity between May 2015 and September 2017.
patients receive two seven-day triple therapy (VAC) per day, VPZ (20 mg), Amasilin (750 mg) and CAM (200 mg).
the researchers assessed the relationship between Helicobacterrobacteria eradication rates, CAM susceptibility and safety.
results showed that 146 patients (middle age: 63 years old, range: 22-85 years old) (60% of whom were women) were treated with VAC, and 131 patients were tested for 13 C-urea exhalation to assess eradication success rates.
prevalence of CAM resistance was 34.2%.
VAC eradication rate in each scenario (PP) and "therapeutic intent" (ITT) analysis was 90.8 per cent (n s 131) and 81.5 per cent (n s 146) respectively.
in the PP analysis of CAM sensitivity, the eradication rate of VAC was statistically different between CAM-sensitive strains (91.6%, n s 83) and CAM drug-resistant strains (89.4%, n s 47).
researchers say the helicobacter pyridobacter strain, which is resistant to CAM, is prevalent in one-third of patients in Japan.
regardless of CAM sensitivity, VPZ-based triple therapy is very effective and well-to-do.
, it may be a valuable first-line treatment for Helicobacterrobacteria infection.
.